Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO by overstating the duration it could fund its operations with existing cash and expected net proceeds from the IPO [1][2]. Group 1: Allegations and Financial Impact - The complaint states that Zenas BioPharma failed to disclose that it could only fund its operations for twelve months instead of the twenty-four months previously claimed in the Registration Statement [2]. - Following the disclosure of these material adverse facts, Zenas BioPharma's share price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 16, 2025, and they do not need to participate in the case to be eligible for recovery [3]. - The class action allows shareholders to act collectively against the alleged wrongdoing of Zenas BioPharma [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [4].

SAN DIEGO, April 18, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering ("IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit.  Captioned Bu ...

Core Viewpoint - A securities class action lawsuit has been filed against Zenas BioPharma, alleging that the company made false and misleading statements regarding its financial stability during its IPO [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Zenas BioPharma securities during the IPO on or around September 13, 2024 [1]. - The complaint claims that the Registration Statement contained misleading information about the company's ability to fund its operations [2]. Group 2: Financial Misrepresentation - It is alleged that Zenas BioPharma overstated the duration it could fund its operations using existing cash and expected IPO proceeds [2]. - The company's quarterly report filed on November 12, 2024, indicated it could fund operations for only twelve months, contrary to the twenty-four months stated in the Registration Statement [3]. Group 3: Impact on Share Price - Following the disclosure of omitted material facts, Zenas BioPharma's share price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% below the IPO price [3].

WASHINGTON, April 17, 2025 (GLOBE NEWSWIRE) -- Investors who lost money on securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) purchased pursuant and/or traceable to the Zenas BioPharma’s September 2024 initial public offering (the “IPO”) are encouraged to contact Cohen Milstein Sellers & Toll PLLC to learn about a recently filed securities class action lawsuit. [Click here for information about joining the class action] CASE BACKGROUND: Zenas BioPharma is a clinical-stage biopharmaceutical company developin ...

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducemen ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. (“Zenas BioPharma” or “the Company”) (NASDAQ: ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquir ...

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”). If you wish to serve as lead plaintiff, you must move th ...

SAN DIEGO, April 16, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO) resulting from allegations that Zenas BioPharma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a co ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...